Microsoft is rolling out a major overhaul of its Windows Insider Program, aiming to simplify how early Windows features are tested while addressing long-standing user complaints around complexity and ...

AI thrives on data but feeding it the right data is harder than it seems. As enterprises scale their AI initiatives, they face the challenge of managing diverse data pipelines, ensuring proximity to ...

Many people are turning to artificial intelligence for personal finance advice. Writing a good AI prompt can mean the difference between receiving a reasonable or poor output, experts said. While AI ...

In this post, we will show you how to skip the consent prompt for RDP connections in Windows Server. Microsoft has released a security update for the Remote Desktop Connection that will show a new ...

Debloat tools claim to make Windows 11 more efficient by removing unnecessary processes and freeing up RAM. In practice, that's not the case. I've been writing about technology for more than 15 years ...

If you have found Windows 11's feature rollouts confusing, Microsoft hears you and is overhauling the Windows Insider Program. Now, instead of three Insider channels, there are just two: Experimental ...

Something to look forward to: Microsoft released new Windows 11 Insider Preview builds to the Canary, Dev, and Beta channels this week, bringing multiple new features for developers and power users.

As TSA lines get longer and the situation at U.S. airports becomes more uncertain, there's a method for flyers hoping to fast-pass security wait times. In addition to keeping tabs on TSA wait-time ...

CNN correspondents and crew members were forced to run for cover in two separate incidents in Israel and Iran due to bombardments overhead. Anchor Erin Burnett and Jerusalem correspondent Jeremy ...

Microsoft and Apple have long felt like the Montagues and the Capulets, but lately, it feels like that feud is gradually mellowing into a cordial, mutual understanding — without needing two young ...

Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases. The discontinuation will ...